Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs H3B-6545 (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Inc; H3 Biomedicine

    • Most Recent Events

    • 04 Jun 2024 Results( At data cutoff (30 Nov 22), n=151 pts ) evaluating effect of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive , HER2 negative breast cancer (BC), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2024 According to a Florida Cancer Specialists & Research Institute media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
    • 22 Dec 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top